A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

por Creelan, Benjamin C., Yeh, Tammie C., Kim, Sang-We, Nogami, Naoyuki, Kim, Dong-Wan, Chow, Laura Q. M., Kanda, Shintaro, Taylor, Rosemary, Tang, Weifeng, Tang, Mei, Angell, Helen K., Roudier, Martine P., Marotti, Marcelo, Gibbons, Don L.
Publicado 2020

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

por Jabbour, Elias, Kantarjian, Hagop, Aldoss, Ibrahim, Montesinos, Pau, Leonard, Jessica, Gomez, David, Baer, Maria, Gambacorti-Passerini, Carlo, Mccloskey, James, Minami, Yosuke, Papayannidis, Cristina, Rocha, Vanderson, Rousselot, Philippe, Vachhani, Pankit, Wang, Eunice, Hennessy, Meliessa, Patel, Niti, Vorog, Alexander, Wang, Bingxia, Yao, Huilan, Yeh, Tammie, Maria Ribera, Josep
Publicado 2023